文献速递胸部肿瘤

一线纳武利尤单抗联合伊匹木单抗加两周期化疗对比单纯化疗(四周期)治疗转移性非小细胞肺癌:CheckMate 9LA 两年患者报告结局

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
PubMed 文献 · Eur J Cancer · 2023-01-28

CheckMate 9LA 研究纳入 719 例无已知敏感性 EGFR/ALK 变异的转移性非小细胞肺癌患者,随机 1:1 接受纳武利尤单抗联合伊匹木单抗加两周期化疗或单纯四周期化疗。最少随访 2 年时,联合组较化疗组延迟了疾病相关症状负担和健康相关生活质量的明确恶化,LCSS ASBI 风险比为 0.62(95%CI 0.45-0.87),并维持了生活质量。

要点

  • 联合组较化疗组延迟 LCSS ASBI 明确恶化,HR 0.62(95%CI 0.45-0.87)。
  • 治疗期两组 LCSS ASBI/3-IGI 和 EQ-5D-3L VAS/UI 较基线均未恶化,但未达最小重要差异。
  • 混合效应模型显示两组症状负担较基线总体减轻,联合组 LCSS 3-IGI 和 EQ-5D-3L VAS/UI 数值上优于化疗组但未达最小重要差异。

核心结论

  • 最少随访 2 年时,一线纳武利尤单抗联合伊匹木单抗加化疗较单纯化疗降低疾病相关症状负担和健康相关生活质量明确恶化的风险,并维持了转移性非小细胞肺癌患者的生活质量。

研究设计与样本

  • CheckMate 9LA(NCT03215706)为随机对照研究,719 例患者按 1:1 随机接受纳武利尤单抗联合伊匹木单抗加两周期化疗或单纯四周期化疗。
  • 采用肺癌症状量表(LCSS)和 3 水平 EQ-5D(EQ-5D-3L)评估疾病相关症状负担和健康相关生活质量。
  • 对治疗期 LCSS 平均症状负担指数(ASBI)、LCSS 三项全局指数(3-IGI)和 EQ-5D-3L 视觉模拟量表(VAS)及效用指数(UI)随时间的变化进行描述性分析和混合效应模型重复测量分析,并进行至恶化/改善时间分析。

主要发现

  • 治疗期患者报告结局问卷完成率>80%。
  • 两组治疗期 LCSS ASBI/3-IGI 和 EQ-5D-3L VAS/UI 的平均变化较基线均未恶化,但未达最小重要差异。
  • 混合效应模型重复测量分析显示两组症状负担较基线总体减轻;联合组较化疗组 LCSS 3-IGI 和 EQ-5D-3L VAS/UI 较基线的变化数值上改善,但未达最小重要差异。
  • 联合组较化疗组延迟至明确恶化时间(LCSS ASBI:风险比 0.62[95%置信区间 0.45-0.87]),各患者报告结局指标结果相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus chemotherapy (4 cycles) in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years). METHODS: In patients (N = 719) randomised 1:1 to nivolumab plus ipilimumab with chemotherapy or chemotherapy alone, disease-related symptom burden and health-related quality of life were assessed using the Lung Cancer Symptom Scale (LCSS) and 3-level EQ-5D (EQ-5D-3L). Treatment-phase changes in LCSS average symptom burden index (ASBI), LCSS three-item global index (3-IGI) and EQ-5D-3L visual analogue scale (VAS) and utility index (UI) over time were analysed descriptively and using mixed-effect model repeated measures. Time-to-deterioration/improvement analyses were conducted. RESULTS: Treatment-phase PRO questionnaire completion rates were >80%. Mean treatment-phase changes showed no deterioration from baseline in both arms for LCSS ASBI/3-IGI and EQ-5D-3L VAS/UI; however, minimally important differences were not met. Mixed-effect model repeated measures analyses showed overall reduction in symptom burden from baseline for both arms; changes from baseline for LCSS 3-IGI and EQ-5D-3L VAS/UI were numerically improved with nivolumab plus ipilimumab with chemotherapy versus chemotherapy, but minimally important differences were not met. Nivolumab plus ipilimumab with chemotherapy delayed time-to-definitive-deterioration versus chemotherapy (LCSS ASBI: hazard ratio, 0.62 [95% confidence interval, 0.45-0.87]); results were similar across PRO measures. CONCLUSIONS: At 2-year minimum follow-up, first-line nivolumab plus ipilimumab with chemotherapy reduced the risk of definitive deterioration in disease-related symptom burden and health-related quality of life versus chemotherapy and maintained QoL in patients with metastatic non-small cell lung cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier, NCT03215706.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. Eur J Cancer. 2023. PMID: 36871487. doi:10.1016/j.ejca.2023.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。